High Variability in Isavuconazole Unbound Fraction in Clinical Practice : A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
© 2023. The Author(s)..
Isavuconazole exposure-response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42-5.30%) in patients. This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole.
| Errataetall: |
CommentIn: Clin Pharmacokinet. 2024 Apr 4;:. - PMID 38573478 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Clinical pharmacokinetics - 62(2023), 12 vom: 11. Dez., Seite 1695-1699 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jansen, Anouk M E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
60UTO373KE |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 16.04.2024 published: Print-Electronic CommentIn: Clin Pharmacokinet. 2024 Apr 4;:. - PMID 38573478 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40262-023-01311-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363125930 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363125930 | ||
| 003 | DE-627 | ||
| 005 | 20240416232318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40262-023-01311-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM363125930 | ||
| 035 | |a (NLM)37819504 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jansen, Anouk M E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High Variability in Isavuconazole Unbound Fraction in Clinical Practice |b A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Pharmacokinet. 2024 Apr 4;:. - PMID 38573478 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Isavuconazole exposure-response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42-5.30%) in patients. This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a isavuconazole |2 NLM | |
| 650 | 7 | |a 60UTO373KE |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Triazoles |2 NLM | |
| 700 | 1 | |a Ter Heine, Rob |e verfasserin |4 aut | |
| 700 | 1 | |a Verweij, Paul E |e verfasserin |4 aut | |
| 700 | 1 | |a Brüggemann, Roger J M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacokinetics |d 1993 |g 62(2023), 12 vom: 11. Dez., Seite 1695-1699 |w (DE-627)NLM000147567 |x 1179-1926 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:12 |g day:11 |g month:12 |g pages:1695-1699 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40262-023-01311-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 12 |b 11 |c 12 |h 1695-1699 | ||